Study: Retratrutide Leads 20% Weight Loss in Diabetes, Heart Patients

Impressive Outcomes from Retatrutide in Clinical Trials

In recent phase 3 clinical trials, the highly anticipated drug retatrutide has shown promising results in terms of weight loss and blood sugar management. The drug manufacturer, Eli Lilly, has revealed that the experimental drug has shown up to almost a 23% decrease in starting body weight, putting it in the running for the most potent weight loss drug for adults with heart disease or type 2 diabetes. The company plans to submit the drug for FDA approval in early 2027.

Retatrutide Emerges as a Potential Obesity Solution

According to Christine Bonarrigo, PharmD, a weight management pharmacist at Tufts Medical Center, “This medication could become one of the most effective pharmacologic options we have for obesity. However, the goal isn’t simply weight loss. It’s reducing obesity-related disease and improving long-term health.”

Retatrutide’s Unique Action Mechanism

Retatrutide works differently from other GLP-1 medications, such as semaglutide and tirzepatide. It is a triple-agonist medication that acts on three different hormone receptors in the body. This unique action mechanism has earned it the “triple G” nickname.

Major Weight Loss Achieved in Type 2 Diabetes Patients

In one of the phase 3 clinical trials, TRIUMPH-2, involving approximately 1,150 adults who were overweight or had obesity and type 2 diabetes, the retatrutide group achieved significant weight loss. For instance, those on a 12mg dose lost about 20.8% of their starting weight.

Retatrutide’s Impact on Severe Obesity and Heart Disease

In another trial, TRIUMPH-3, involving nearly 2,000 adults with severe obesity and heart disease, retatrutide also showed substantial weight loss results. Participants on a 12 mg dose lost about 22.6% of their starting weight.

Side Effects of Retatrutide

While the results are promising, retatrutide is not without side effects. The most commonly reported ones include diarrhea, nausea, constipation, decreased appetite, and vomiting. The high occurrence of these side effects led to more than 1 in 10 participants dropping out of the trial.